PortfoliosLab logo
CORT vs. AXSM
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CORT and AXSM is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

CORT vs. AXSM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Corcept Therapeutics Incorporated (CORT) and Axsome Therapeutics, Inc. (AXSM). The values are adjusted to include any dividend payments, if applicable.

800.00%1,000.00%1,200.00%1,400.00%1,600.00%1,800.00%2,000.00%2,200.00%NovemberDecember2025FebruaryMarchApril
1,137.38%
1,095.19%
CORT
AXSM

Key characteristics

Sharpe Ratio

CORT:

1.36

AXSM:

1.12

Sortino Ratio

CORT:

3.88

AXSM:

1.98

Omega Ratio

CORT:

1.52

AXSM:

1.23

Calmar Ratio

CORT:

3.65

AXSM:

1.36

Martin Ratio

CORT:

12.82

AXSM:

6.03

Ulcer Index

CORT:

12.96%

AXSM:

8.59%

Daily Std Dev

CORT:

121.83%

AXSM:

46.26%

Max Drawdown

CORT:

-94.28%

AXSM:

-86.65%

Current Drawdown

CORT:

-45.51%

AXSM:

-24.17%

Fundamentals

Market Cap

CORT:

$6.57B

AXSM:

$5.09B

EPS

CORT:

$1.23

AXSM:

-$5.99

PEG Ratio

CORT:

0.61

AXSM:

0.00

PS Ratio

CORT:

9.73

AXSM:

13.21

PB Ratio

CORT:

9.66

AXSM:

89.35

Total Revenue (TTM)

CORT:

$528.23M

AXSM:

$310.69M

Gross Profit (TTM)

CORT:

$519.89M

AXSM:

$283.69M

EBITDA (TTM)

CORT:

$107.91M

AXSM:

-$209.15M

Returns By Period

The year-to-date returns for both stocks are quite close, with CORT having a 23.52% return and AXSM slightly lower at 23.46%.


CORT

YTD

23.52%

1M

8.07%

6M

25.11%

1Y

171.20%

5Y*

38.38%

10Y*

25.54%

AXSM

YTD

23.46%

1M

-17.27%

6M

11.90%

1Y

53.84%

5Y*

8.50%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CORT vs. AXSM — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CORT
The Risk-Adjusted Performance Rank of CORT is 9696
Overall Rank
The Sharpe Ratio Rank of CORT is 9191
Sharpe Ratio Rank
The Sortino Ratio Rank of CORT is 9898
Sortino Ratio Rank
The Omega Ratio Rank of CORT is 9797
Omega Ratio Rank
The Calmar Ratio Rank of CORT is 9898
Calmar Ratio Rank
The Martin Ratio Rank of CORT is 9797
Martin Ratio Rank

AXSM
The Risk-Adjusted Performance Rank of AXSM is 8787
Overall Rank
The Sharpe Ratio Rank of AXSM is 8787
Sharpe Ratio Rank
The Sortino Ratio Rank of AXSM is 8686
Sortino Ratio Rank
The Omega Ratio Rank of AXSM is 8282
Omega Ratio Rank
The Calmar Ratio Rank of AXSM is 8989
Calmar Ratio Rank
The Martin Ratio Rank of AXSM is 9090
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CORT vs. AXSM - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Corcept Therapeutics Incorporated (CORT) and Axsome Therapeutics, Inc. (AXSM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for CORT, currently valued at 1.36, compared to the broader market-2.00-1.000.001.002.003.00
CORT: 1.36
AXSM: 1.12
The chart of Sortino ratio for CORT, currently valued at 3.88, compared to the broader market-6.00-4.00-2.000.002.004.00
CORT: 3.88
AXSM: 1.98
The chart of Omega ratio for CORT, currently valued at 1.52, compared to the broader market0.501.001.502.00
CORT: 1.52
AXSM: 1.23
The chart of Calmar ratio for CORT, currently valued at 3.65, compared to the broader market0.001.002.003.004.00
CORT: 3.65
AXSM: 1.36
The chart of Martin ratio for CORT, currently valued at 12.82, compared to the broader market-5.000.005.0010.0015.0020.00
CORT: 12.82
AXSM: 6.03

The current CORT Sharpe Ratio is 1.36, which is comparable to the AXSM Sharpe Ratio of 1.12. The chart below compares the historical Sharpe Ratios of CORT and AXSM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00NovemberDecember2025FebruaryMarchApril
1.36
1.12
CORT
AXSM

Dividends

CORT vs. AXSM - Dividend Comparison

Neither CORT nor AXSM has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CORT vs. AXSM - Drawdown Comparison

The maximum CORT drawdown since its inception was -94.28%, which is greater than AXSM's maximum drawdown of -86.65%. Use the drawdown chart below to compare losses from any high point for CORT and AXSM. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%NovemberDecember2025FebruaryMarchApril
-45.51%
-24.17%
CORT
AXSM

Volatility

CORT vs. AXSM - Volatility Comparison

Corcept Therapeutics Incorporated (CORT) has a higher volatility of 81.19% compared to Axsome Therapeutics, Inc. (AXSM) at 16.05%. This indicates that CORT's price experiences larger fluctuations and is considered to be riskier than AXSM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%NovemberDecember2025FebruaryMarchApril
81.19%
16.05%
CORT
AXSM

Financials

CORT vs. AXSM - Financials Comparison

This section allows you to compare key financial metrics between Corcept Therapeutics Incorporated and Axsome Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items